TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical Holdings Group Ltd. announced a capital increase agreement involving its subsidiary, Meifu Company. The agreement will see Meifu Company’s registered capital rise from RMB1 million to RMB50 million, with Meiyan Space and Hainan Temmei contributing RMB25.5 million and RMB23.5 million, respectively. This move will result in Meiyan Space holding a 51% stake, making Meifu Company a subsidiary of Sihuan Pharmaceutical. The capital increase is aimed at leveraging Meifu Company’s resources and expertise in the medical aesthetics field, enhancing market presence, and mitigating competition risks.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and sales of pharmaceutical products. The company is involved in the medical aesthetics sector, providing equipment and devices, and aims to expand its market presence in China.
YTD Price Performance: -2.00%
Technical Sentiment Signal: Strong Buy
Current Market Cap: $719.7M
See more insights into 0460 stock on TipRanks’ Stock Analysis page.